CHEK1 and breast cancer: Nonetheless, the present study has been performed on several different cell lines widely used to model ERα-positive primary and metastatic BC that have been treated with different CHK1 inhibitors and with the drugs used to treat women carrying primary (i.e., Tam) or metastatic (i.e., palbociclib and abemaciclib) breast tumors.